There is plenty of evidence that ProGRP (along with NSE, the TM we were unable to measure in plasma) are diagnostic biomarkers for SCLC [11] and other neuroendocrine tumours, but the apparent association with earlier stage is intriguing, especially as most SCLC tested were late stage. This evidence concerns the gene GRP and small cell lung carcinoma.